Lisata Therapeutics, Valo Therapeutics enter preclinical research collaboration
Lisata Therapeutics (LSTA) and Valo Therapeutics announced a preclinical research collaboration to investigate the benefits of combining Lisata’s novel product candidate, certepetide, with ValoTx’s platform technology, PeptiCRAd, and a checkpoint inhibitor in a melanoma mouse model. Under the agreement, ValoTx will be conducting the research, while Lisata will supply certepetide product.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on LSTA:
TipRanks is the most comprehensive data set of sell side analysts and hedge fund managers. TipRanks' multi-award winning platform ranks financial experts based on measured performance and the accuracy of their predictions so investors know who to trust when making investment decisions.